| 查看: 183 | 回复: 1 | |||
| 当前主题已经存档。 | |||
[交流]
【求助】药物临床材料英翻中 已有1人参与
|
|||
|
The primary endpoints of the study were to assess , the changes in severity of hemorrhage during the use of Futhan. The severity of hemorrhage after Futhan-used hemodialysis was evaluated by measuring the percentage of subjects, such that the same test as initially conducted test were conducted within 2 days after completion of the final Futhan-used hemodialysis. After the final completion of Futhan-used hemodialysis, the hemorrhage test was conducted to compare the severity of hemorrhage prior to use of Futhan. The changes in the severity of hemorrhage were objectively assessed in accordance with the following scale: I. (reduced), II. (no change), III. (slightly increased), and IV (significantly increased). The scales (III, IV) were assessed as the worsening of hemorrhage). Table 11 shows the changes in the severity of hemorrhage, calculated by the number and percentage of patients per drug. The study protocol dictated that the primary endpoints were to assess during the use of Futhan only in consideration of subjects’ safety. However, during heparin-used hemodialysis, increased severity in hemorrhage was reported by 1 patient and thus related data were presented as a reference. Data on the changes in the severity of hemorrhage after Futhan-used hemodialysis showed that of 49 subjects, reduced and no-change hemorrhages was reported by 35 and 14, respectively, thus representing 100% efficacy (PP analysis). In the ITT analysis, the increased severity of hemorrhage in 54 subjects was not observed and thus the same outcome the per-protocol analysis was obtained. Despite heparin-used hemodialysis in 22 patients who did not occur hemorrhage yet or recovered from hemorrhage completely, there was a slight increase in hemorrhage in 1 patient (94.5%). ITT analysis had a similar result. 谢谢 |
回复此楼» 猜你喜欢
实验室接单子
已经有3人回复
-
要不要辞职读博？
已经有5人回复
-
不自信的我
已经有10人回复
-
磺酰氟产物，毕不了业了！
已经有8人回复
-
求助:我三月中下旬出站，青基依托单位怎么办？
已经有10人回复
-
26申博（荧光探针方向，有机合成）
已经有4人回复
-
论文终于录用啦！满足毕业条件了
已经有26人回复
-
2026年机械制造与材料应用国际会议 （ICMMMA 2026）
已经有4人回复
-
Cas 72-43-5需要30g，定制合成，能接单的留言
已经有8人回复
-
北京211副教授，35岁，想重新出发，去国外做博后，怎么样？
已经有8人回复
» 本主题相关商家推荐: (我也要在这里推广)
Dream.0123
金虫 (小有名气)
- 应助: 0 (幼儿园)
- 金币: 523.5
- 帖子: 59
- 在线: 11小时
- 虫号: 599853
- 注册: 2008-09-11
- 专业: medicinal chemistry
jeipee(金币+70): 2010-04-09 12:28
|
本实验是为了评估使用甲磺酸卡萘司他后出血程度的改变。通过受试者的比例来评价使用甲磺酸卡萘司他进行血液透析后的出血程度，与最初相同的对照试验是在完成最后一次使用甲磺酸卡萘司他血液透析后两天内进行。 最后一次使用甲磺酸卡萘司他血液透析后，进行出血试验，与使用甲磺酸卡萘司他之前的出血程度做比较。用以下等级客观地表示出血严重性的变化，I.（减少），II.（无变化），III.（略有增加），IV.（明显增加）。III, IV等级被视为出血情况恶化。 表11反映了出血严重性的变化，以病人数量和每种药物的病人的百分比计算 本实验方案的原则是在受试者安全的前提下，评估使用甲磺酸卡萘司他后出血严重性的变化。但是，在使用肝素血液透析试验中，报告了一例出血严重性增加，因此相关数据作为参考。 使用甲磺酸卡萘司他后出血严重性的变化数据表明，49例受试者中，出血减少和无变化分别为35例和14例，因此使用甲磺酸卡萘司他血液透析100%有效（PP分析）。在 ITT（指示剂时间试验？）分析中，54例中没有观察到出血严重性增加，因此与符合方案分析结果一致。 尽管22例使用肝素血液透析患者，这些患者都没有发生出血或者出血情况已经完全没有了，但是还是有一例报告出血严重性增加（94.5%）。ITT分析结果相似。 |
2楼2010-04-09 12:28:02